{
    "clinical_study": {
        "@rank": "4678", 
        "arm_group": {
            "arm_group_label": "Radiotherapy followed by chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and tolerability of radiotherapy\n      followed by adjuvant chemotherapy in stage I/II NK/T-cell lymphoma."
        }, 
        "brief_title": "Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Extranodal NK/T-cell Lymphoma, Nasal Type", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, Extranodal NK-T-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "For patients with stage I/II NK/T-cell lymphoma, the sequence of radiotherapy and\n      chemotherapy is controversial. Some studies demonstrated the advantage of upfront\n      radiotherapy. Therefore, we designed this single-arm phase II study to evaluate the efficacy\n      and safety of radiotherapy followed by adjuvant chemotherapy with DICE regimen plus\n      peg-asparaginase which was proved to be effective in NK/T-cell lymphoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age range 14-70 years old\n\n          -  Histological confirmed, previously untreated stage I/II NK/T cell lymphoma in the\n             upper-aerodigestive tract\n\n          -  ECOG performance status 0-1\n\n          -  Life expectancy of more than 3 months\n\n          -  Without prior history of pancreatitis\n\n          -  Adequate bone marrow and organ functions\n\n        Exclusion Criteria:\n\n          -  Low risk population (Definition: stage I without local invasion, B symptoms and high\n             LDH level)\n\n          -  Pregnant or lactating women\n\n          -  With contraindication of steroid including uncontrolled diabetes\n\n          -  Serious uncontrolled diseases and intercurrent infection\n\n          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma\n             in-situ of uterine cervix"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667302", 
            "org_study_id": "LMTG 12-02"
        }, 
        "intervention": {
            "arm_group_label": "Radiotherapy followed by chemotherapy", 
            "description": "Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1", 
            "intervention_name": "Radiotherapy followed by chemotherapy", 
            "intervention_type": "Drug", 
            "other_name": "DXM, IFO, VP-16, DDP, PEG-ASP"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NK/T-cell lymphoma", 
            "Radiotherapy", 
            "Adjuvant chemotherapy"
        ], 
        "lastchanged_date": "March 2, 2013", 
        "location": {
            "contact": {
                "email": "pattrick_guo@msn.com", 
                "last_name": "Ye Guo, MD", 
                "phone": "862164175590"
            }, 
            "facility": {
                "address": {
                    "city": "SHanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma", 
        "overall_contact": {
            "email": "pattrick_guo@msn.com", 
            "last_name": "Ye Guo, MD", 
            "phone": "862164175590"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Ye Guo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "3-year Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667302"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Ye Guo", 
            "investigator_title": "Assocaite Director of Medical Oncology Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "3-year overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}